Literature DB >> 20465598

Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases.

Xin Wang1, Ying Zhao, Xuchen Cao.   

Abstract

Occult breast carcinoma presenting axillary metastases is uncommon and accounts for less than 1% of newly diagnosed breast carcinoma. However, it continues to be a challenging diagnostic and therapeutic problem. In this study, we analyzed retrospectively on 51 cases of occult breast cancer from 1990 to 2003 in our hospital. All these patients had a palpable axillary nodule, no dominant breast mass, and no abnormal mammograms and breast ultrasonograph. Histological examination of axillary mass revealed metastasis from breast. The positive rate of estrogen receptor, progesterone receptor and the monoclonal antibody M4G3 against human breast cancer showed 62.7%, 66.7%, and 93.1% positive respectively. Among 51 cases, 38 cases received mastectomy whereas 13 cases had no local treatment of the breast. The primary tumors were detected in 28 of 38 cases having mastectomy by pathology. Seventy-seven percent of patients who had no local treatment of the breast had a tumor recurrence, compared with 26% who had a mastectomy. The mean disease-free survival was 23 months in patients who had no local treatment of the breast, compared with 76 months in patients who had mastectomy. Eight of the 13 patients who had no treatment with breast died whereas seven of the 38 who had local treatment died, with a mean follow-up of 73 months. It was found that patients having mastectomy had a better disease-free survival (p < 0.001) and overall survival (p < 0.001) compared with those having no local treatment of the breast. Once the diagnosis of occult breast carcinoma is clarified, an axillary dissection and the local treatment of breast should be carried out.

Entities:  

Mesh:

Year:  2010        PMID: 20465598     DOI: 10.1111/j.1524-4741.2009.00848.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  7 in total

1.  Clinicopathologic characteristics of malignant non-hematopoietic tumors first presented as an axillary mass with emphasis on occult breast carcinoma.

Authors:  Thaer Khoury; Ana Lucia Ruano Mendez; Xuan Peng; Li Yan; Emilian Racila
Journal:  Int J Clin Oncol       Date:  2019-10-04       Impact factor: 3.402

2.  Survival outcomes of different treatment methods for the ipsilateral breast of occult breast cancer patients with axillary lymph node metastasis: a single center experience.

Authors:  Sang Min Woo; Byung Ho Son; Jong Won Lee; Hee Jeong Kim; Jong Han Yu; Beom Seok Ko; Guiyun Sohn; Yu Ra Lee; Hanna Kim; Sei Hyun Ahn; Seung Hee Baek
Journal:  J Breast Cancer       Date:  2013-12-31       Impact factor: 3.588

Review 3.  Occult breast cancer: Where are we at?

Authors:  Adam Ofri; Katrina Moore
Journal:  Breast       Date:  2020-10-27       Impact factor: 4.380

4.  Clinicopathological characteristics and treatment outcomes of occult breast cancer: a population-based study.

Authors:  Zijun Zhao; Ting Zhang; Yu Yao; Xin Lu
Journal:  BMC Surg       Date:  2022-04-17       Impact factor: 2.030

Review 5.  Male occult breast cancer with axillary lymph node metastasis as the first manifestation: A case report and literature review.

Authors:  Ruixin Xu; Jianbin Li; Yingjie Zhang; Hongbiao Jing; Youzhe Zhu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

6.  Comparable Survival between Additional Radiotherapy and Local Surgery in Occult Breast Cancer after Axillary Lymph Node Dissection: A Population-based Analysis.

Authors:  San-Gang Wu; Wen-Wen Zhang; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Yong-Xiong Chen; Zhen-Yu He
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

7.  Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study.

Authors:  Li-Ping Ge; Xi-Yu Liu; Yi Xiao; Zong-Chao Gou; Shen Zhao; Yi-Zhou Jiang; Gen-Hong Di
Journal:  Cancer Manag Res       Date:  2018-10-09       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.